The lastest scientific findings at the service of the fight against cancer
The orthotopic implantation of human tumors in mice allows Xenopat to provide services assisting anticancer drug development and personalized cancer treatment. Xenopat’s services focus on two main fields:
Advanced Preclinical Services
Xenopat offers researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available. Xenopat offers researchers the OrthoXenoBank®, which is composed of several orthotopic models of different tumor types (orthoxenografts®), characterized at histological and genetic levels, with different sensitivity to diverse chemotherapies.
Personalized Cancer Treatment
Xenopat offers healthcare professionals and patients the most advanced technology in order to select the best treatment in the fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model allows us to test several drugs and find the best therapy for each patient.
Xenopat is a company, spin-off of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB).